Sorrento receives grant from NIH to study antibacterial drug delivery

The U.S. National Institutes of Health granted Sorrento Therapeutics ($SRNE) $2.6 million to develop antibacterial immunotherapies, including $600,000 for targeted drug delivery of a novel monoclonal antibody targeting Pseudomonas aeruginosa, which causes pneumonia and other illnesses. This marks another government effort to address growing concerns about the lack of new antibiotics as well as the emergence of drug-resistant strains of bacteria. The federal Centers for Disease Control and Prevention estimates that there are 51,000 healthcare-associated infections due to the bacteria, and 13% are drug resistant. Release

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…